Spring loaded fixation element insertion device

The invention relates to a device for attaching fixation elements to bone, having a longitudinal member with a channel extending therein adapted for receiving at least one fixation element. A shaft extends within the channel and is positioned coaxially within at least a portion of the longitudinal member and at least a portion of the shaft is retained within the longitudinal member and a distal end of the shaft is configured and adapted to contact at least a portion of the fixation element received within the longitudinal member. A spring is positioned adjacent the shaft for resiliently biasing the shaft in an axial direction and the shaft is moveable with respect to the longitudinal member to drive the fixation element into bone.

Compositions and methods related to nucleic acid synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Novel use

The invention relates to the use of polyphosphate containing species in a method of nucleic acid synthesis, to methods of nucleic acid synthesis, and to the use of kits comprising said polyphosphate containing species. The invention also relates to the use of polyphosphate containing species for the capping of 3'-terminal hydroxyl moieties using terminal transferases.

COMPOSITIONS AND METHODS RELATED TO NUCLEIC ACID PREPARATION

The invention relates to a method of nucleic acid synthesis comprising the use of 3′-O-azidomethyl blocked nucleotide triphosphates which comprises the step of adding a capping group to any uncleaved 3′-O-azidomethyl groups and to the use of kits comprising said capping groups in a method of nucleic acid synthesis. The invention also relates to capped nucleotide triphosphates and 3′-O-azidomethyl capping groups. 1. A method of treating an oligonucleotide , which comprises the steps of:(a) providing an oligonucleotide with a 3′-O-azidomethyl group an initiator sequence; and(b) treating the 3′-O-azidomethyl group via a 1,3-dipolar cycloaddition reaction to prevent subsequent cleavage of the 3′-O-azidomethyl group.2. The method as defined in claim 1 , wherein the 3′-O-azidomethyl group is treated with an irreversible capping group.3. The method as defined in claim 2 , wherein the capping group is a dipolarophile.4. The method as defined in claim 3 , wherein the dipolarophile is an alkyne claim 3 , such as a strained alkyne.5. The method as defined in claim 3 , wherein the dipolarophile is dibenzocyclooctyne-amine.6. The method as defined in claim 1 , wherein the 1 claim 1 ,3-dipolar cycloaddition reaction of step (b) comprises an uncatalysed cycloaddition reaction.7. The method as defined in claim 1 , wherein the 1 claim 1 ,3-dipolar cycloaddition reaction of step (b) comprises a cycloaddition reaction catalysed by a copper or ruthenium-based catalyst.8. The method as defined in claim 2 , wherein the capping group comprises biotin.9. The method as defined in claim 2 , wherein the capping group comprises a fluorine containing moiety.10. The method as defined in claim 2 , wherein the capping group comprises a fluorescent moiety.1216-. (canceled)17. The method as defined in claim 1 , wherein the capping group is an alkyne containing reagent.20. (canceled) This application is a continuation of U.S. patent application Ser. No. 15/555,232 filed Sep. 1, 2017, which is a ...

Novel Use

The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties per se and a process for preparing nucleotide triphosphates comprising said amine masked moieties. 1. A method of enzymatic nucleic acid synthesis , comprising:(i) providing an amine masked derivative of a nitrogenous heterocycle, and(ii) incorporating the amine masked derivative into a nucleic acid molecule.4. The method of claim 2 , wherein the compound of formula (I) is selected from a compound of formula (I)to (I) claim 2 , such as (I).5. The method of claim 2 , wherein X represents an —OH group or a triphosphate group.6. The method of claim 2 , wherein the hydrogen bond base-pairing is selected from: Watson-Crick claim 2 , Hoogsteen claim 2 , or alternative/expanded genetic code base pairing.7. The method of claim 2 , wherein Rand Rindependently represent —H claim 2 , —OH claim 2 , —ONH claim 2 , —ONC(CH) claim 2 , —OCHN claim 2 , —OCHCHCH claim 2 , —OPO claim 2 , —OCHSSCHCH claim 2 , —OCOCH claim 2 , —OCHCHCN claim 2 , —O-methoxyethyl claim 2 , —O-alkyl claim 2 , or —O-alkoxy or a hydroxy protecting group.8. The method of claim 2 , wherein Ris selected from azide (—N) claim 2 , benzoylamine (N-benzoyl or —NHCOPh) claim 2 , N-methyl claim 2 , (—NHMe) claim 2 , isobutyrylamine claim 2 , dimethylformamidylamine claim 2 , 9-fluorenylmethyl carbamate claim 2 , t-butyl carbamate claim 2 , benzyl carbamate claim 2 , acetamide (N-acetyl or —NHCOMe) claim 2 , trifluoroacetamide claim 2 , pthlamide claim 2 , benzylamine (N-benzyl or —NH—CH-phenyl) claim 2 , triphenylmethylamine claim 2 , benxylideneamine claim 2 , tosylamide claim 2 , isothiocyanate claim 2 , an N-allyl group claim 2 , (such as N-dimethylallyl (—NHCH—CH═CH)) and an N-anisoyl (—NHCOPh-OMe) group claim 2 , such as azide (—N) claim 2 , N-acetyl (—NHCOMe) claim 2 , N-benzyl (—NH—CH-phenyl) claim 2 , N-anisoyl (—NHCOPh-OMe) claim 2 , N-methyl ...

Polypropylene compositions methods of making the same

This invention relates to propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from 4.0 to 20.0. The propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages. The composition may comprise isotactic homopolymer in one embodiment, and have a hexane extractables of less than 2 wt % in one embodiment. The composition is useful in making films.

System and method for providing on-line advertising and information

A system and method are disclosed in which an initiating caller using a station connected to a data network receives advertisement information while waiting for a call to complete between the station and the receiving party. The station connects with a server that can access a database storing a plurality of advertisement information. The station includes a user interface, which allows the caller to interact with the station, and a flow controller, which monitors the bandwidth available to receive information from the server system.

DEUTERIUM-ENRICHED PIRFENIDONE AND METHODS OF USE THEREOF

Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Articles formed from propylene diene copolymers

The co-polymerization reaction of one or more olefin monomers, such as propylene, with α,ω-diene units and the resulting copolymers are provided. More specifically, the copolymer may have from 90 to 99.999 weight percent of olefins and from 0.001 to 2.000 weight percent of α,ω-dienes. The copolymer may have a weight average molecular weight in the range from 50,000 to 2,000,000, a crystallization temperature in the range from 115° C. to 135° C. and a melt flow rate in the range from 0.1 dg/min to 100 dg/min. These copolymers may be employed in a wide variety of applications, the articles of which include, for example, films, fibers, such as spunbonded and meltblown fibers, fabrics, such as nonwoven fabrics, and molded articles. The copolymer may further include at least two crystalline populations. Desirably, the melting point range of one of the crystalline populations is distinguishable from the melting point range of another crystalline population by a temperature range of from 1° C. to 8° C. More desirably, one of the crystalline populations has a melting point in the range from 152° C. to 158° C. and another crystalline population has a melting point in the range from 142° C. to 148° C.

Compositions and Methods Related to Nucleic Acid Synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Compositions and methods for treating or preventing pneumococcal infection

The invention provides polypeptides, polysaccharide-polypeptide conjugates, and expression vectors for treating or preventing pneumococcal infection. The compositions induce an anti-pneumococcal immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response in an infected individual.

System and method for providing on-line advertising and information

A system and method are disclosed in which an initiating caller using a station connected to a data network receives advertisement information while waiting for a call to complete between the station and the receiving party. The station connects with a server that can access a database storing a plurality of advertisement information. The station includes a user interface, which allows the caller to interact with the station, and a flow controller, which monitors the bandwidth available to receive information from the server system.

A Process for the Preparation of Nucleic Acid by Means of 3'-O-Azidomethyl Nucleotide Triphosphate

The invention relates to a method of nucleic acid synthesis comprising the use of 3′-O-azidomethyl blocked nucleotide triphosphates which comprises the step of adding a capping group to any uncleaved 3′-O-azidomethyl groups and to the use of kits comprising said capping groups in a method of nucleic acid synthesis. The invention also relates to capped nucleotide triphosphates and 3′-O-azidomethyl capping groups.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or parallel polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Method and system for providing voice communication over data networks

A method and system are disclosed in which an Internet subscriber can establish real-time voice conversations over the Internet. By performing a call negotiation scheme to identify and locate the other calling party, an Internet telephone can establish a voice communication channel over the Internet to a telephony or computer device.

Indicating Current Connection Status of a Wireless Device

In one embodiments, a method includes determining a current connection status of a first wireless device with respect to one or more second wireless devices configured to communicate wirelessly by a particular wireless communication protocol. The current connection status of the first wireless device potentially being that the first wireless device has scanned for and found one or more available ones of the second wireless devices to connect wirelessly to but has not yet having established a wireless connection to any one of them or potentially being that the first wireless device is currently attempting to establish a wireless connection to one of the available ones of the second wireless devices. The method includes communicating for presentation to a user at the first wireless device a scan-result indicator if the first wireless device has scanned for and found one or more available ones of the second wireless devices to connect wirelessly to but has not yet established a wireless connection ...

System and method for anhedonia measurement using acoustic and contextual cues

This application provides a system for classifying a status of anhedonia, the system including an audio data collector adapted to collect a sample of speech, and a processing module including an audio feature extractor and a classification unit, wherein the audio feature extractor extracts a plurality of acoustic features from the sample of speech, and the classification unit classifies a status of anhedonia from the plurality of acoustic features.

Compositions and methods related to nucleic acid synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

DEUTERIUM-ENRICHED PIRFENIDONE AND METHODS OF USE THEREOF

Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Compositions and methods for treating or preventing pneumococcal infection

The invention provides polypeptides, polysaccharide-polypeptide conjugates, and expression vectors for treating or preventing pneumococcal infection. The compositions induce an anti-pneumococcal immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response in an infected individual.

COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOCOCCAL INFECTION

The invention provides polypeptides, polysaccharide-polypeptide conjugates, and expression vectors for treating or preventing pneumococcal infection. The compositions induce an anti-pneumococcal immune response when administered to a mammal. The compositions can be used prophylactically to vaccinate an individual and/or therapeutically to induce a therapeutic immune response in an infected individual.

Fixation element insertion device

The invention relates to a device for attaching fixation elements to bone, having a longitudinal member with a channel extending therein adapted for receiving at least one fixation element. A shaft extends within the channel and is positioned coaxially within at least a portion of the longitudinal member and at least a portion of the shaft is retained within the longitudinal member and a distal end of the shaft is configured and adapted to contact at least a portion of the fixation element received within the longitudinal member. The longitudinal member is moveable with respect to the shaft to drive the fixation element into bone.

System and method for providing multimedia jitter buffer adjustment for packet-switched networks

A system and method is disclosed for providing dynamic multimedia jitter buffer adjustment for packet-switched networks. The system temporarily stores an amount of incoming data, which is dynamically adjustable, for an amount of time before sending the data out in a more even stream. The system includes a decoder clock, a jitter buffer, a network jitter statistics collector, and a jitter buffer controller. The decoder clock indicates the arrival-time of the data at the system, while the network jitter statistics collector collects the playback-time of that data. By comparing the arrival-time and the playback-time, the jitter buffer controller determines whether the data arrived on schedule. Accordingly, the depth of the jitter buffer can be adjusted to accommodate the late or early arriving data.

Compositions and Methods Related to Nucleic Acid Synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis. 138-. (canceled)39. A method of nucleic acid synthesis , which comprises:(a) providing an initiator oligonucleotide immobilised on a solid support; and(b) adding a 3′-blocked nucleoside triphosphate to said initiator in the presence of a terminal deoxynucleotidyl transferase (TdT) comprising an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOS: 1 to 5 and 8 or a fragment of at least 300 amino acids thereof.40. The method as defined in claim 39 , further comprising the steps of:(c) removal of all reagents from the initiator oligonucleotide;(d) cleaving the blocking group from the 3′-blocked nucleoside in the presence of a cleaving agent; and(e) removal of the cleaving agent.41. The method as defined in claim 39 , wherein the terminal deoxynucleotidyl transferase (TdT) comprises an amino acid sequence having at least 95% sequence identity to SEQ ID NO: 8 or a fragment of at least 300 amino acids thereof.42. The method as defined in claim 40 , wherein greater than 1 nucleotide is added by repeating steps (b) to (e).43. The method as defined in claim 39 , wherein the 3′-blocked nucleoside triphosphate is blocked by either a 3′-O-azidomethyl claim 39 , 3′-aminoxy or 3′-O-allyl group.44Saccharomyces cerevisiae.. The method as defined in claim 39 , wherein the terminal deoxynucleotidyl transferase (TdT) is added in the presence of an extension solution comprising one or more buffers claim 39 , such as Tris or cacodylate claim 39 , one or more salts claim 39 , and inorganic pyrophosphatase claim 39 , such ...

Azidomethyl Ether Deprotection Method

The invention relates to a method of converting an azidomethyl ether substituent to a free hydroxyl group. The invention also relates to methods of nucleic acid synthesis and sequencing comprising the use of nucleotide triphosphates having a 3′-O-azidomethyl substituent, to kits comprising nucleotide triphosphates having a 3′-O-azidomethyl substituent and photoactivatable transition metal complex and to the use of said kits in methods of nucleic acid synthesis and sequencing. 1. A method of converting an azidomethyl ether substituent to a free hydroxyl group wherein said method comprises the step of exposing a compound having said azidomethyl ether substituent to a photoactivated transition metal complex.2. The method as defined in claim 1 , wherein the photoactivated transition metal complex comprises a transition metal selected from ruthenium claim 1 , platinum claim 1 , palladium claim 1 , rhodium and osmium.3. The method as defined in claim 2 , wherein the transition metal is ruthenium.4. The method as defined in any one of to claim 2 , wherein the photoactivated transition metal complex comprises a ligand which is a mono-dentate or bidentate ligand selected from phosphine claim 2 , thiocynate claim 2 , nitrogen claim 2 , pyridine claim 2 , phenanthroline claim 2 , cyclopentadienyl and N-heterocyclic carbine based ligands.5. The method as defined in claim 4 , wherein the photoactivated transition metal complex comprises a pyridine ligand claim 4 , such as a bipyridine ligand.6. The method as defined in claim 5 , wherein the photoactivated transition metal complex is tris(2 claim 5 ,2′-bipyridyl)ruthenium(II)).7. The method as defined in any one of to claim 5 , wherein the azidomethyl ether is present on a ribose or deoxyribose sugar moiety.8. The method as defined in claim 7 , wherein the azidomethyl ether is a 2′ or 3′-O-azidomethyl.9. The method as defined in any one of to claim 7 , which comprises the step of exposing a compound having said azidomethyl ether ...

SYSTEM AND METHOD FOR ANHEDONIA MEASUREMENT USING ACOUSTIC AND CONTEXTUAL CUES

This application provides a system for classifying a status of anhedonia, the system including an audio data collector adapted to collect a sample of speech, and a processing module including an audio feature extractor and a classification unit, wherein the audio feature extractor extracts a plurality of acoustic features from the sample of speech, and the classification unit classifies a status of anhedonia from the plurality of acoustic features. 1. A system for classifying a status of anhedonia , the system comprising:an audio data collector adapted to collect a sample of speech; anda processing module including an audio feature extractor and a classification unit;wherein the audio feature extractor extracts a plurality of acoustic features from the sample of speech, and the classification unit classifies a status of anhedonia from the plurality of acoustic features.2. The system of claim 1 , further comprising:a contextual data collector and a display unit;wherein the contextual data collector collects contextual health data, and the display unit displays a classification result.3. The system of claim 1 , wherein the audio data collector comprises:a microphone for converting an acoustic energy into a voltage signal;an operational amplifier coupled to the microphone for amplifying the voltage signal; andan analog-to-digital converter for converting the voltage signal into digital data.4. The system of claim 1 , wherein the audio data collector comprises: a microphone for converting an acoustic energy into a voltage signal;', 'an operational amplifier coupled to the microphone for amplifying the voltage signal; and', 'an analog-to-digital converter for converting the voltage signal into digital data;, 'a plurality of audio signal capture units, each audio signal capture unit includingan audio data transmitter coupled to an output of the plurality of the audio signal capture units, the audio data transmitter transmits the digital data; andwherein the processing ...

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or parallel polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

System and method for providing multimedia jitter buffer adjustment for packet-switched networks

A system and method is disclosed for providing dynamic multimedia jitter buffer adjustment for packet-switched networks. The system temporarily stores an amount of incoming data, which is dynamically adjustable, for an amount of time before sending the data out in a more even stream. The system includes a decoder clock, a jitter buffer, a network jitter statistics collector, and a jitter buffer controller. The decoder clock indicates the arrival-time of the data at the system, while the network jitter statistics collector collects the playback-time of that data. By comparing the arrival-time and the playback-time, the jitter buffer controller determines whether the data arrived on schedule. Accordingly, the depth of the jitter buffer can be adjusted to accommodate the late or early arriving data.

NOVEL USE

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis. 1. A method of nucleic acid synthesis comprising a step of providing a terminal deoxynucleotidyl transferase (TdT) enzyme comprising an amino acid sequence having at least 95% sequence identity to any one of SEQ ID NOs: 1 to 5 and 8 , such as any of SEQ ID NOs: 1 , 2 , or 8.2. (canceled)3. A method of nucleic acid synthesis , comprising steps of:(a) providing an initiator sequence;{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, '(b) adding a 3′-blocked nucleotide triphosphate to said initiator sequence in the presence of a terminal deoxynucleotidyl transferase (TdT) as defined in ;'}(c) removal of all reagents from the initiator sequence;(d) cleaving the blocking group from the 3′-blocked nucleotide triphosphate in the presence of a cleaving agent; and(e) removal of the cleaving agent.4. The method as defined in claim 3 , wherein greater than 1 nucleotide is added by repeating steps (b) to (e).5. The method as defined in claim 3 , wherein the 3′-blocked nucleotide triphosphate is blocked by either a 3′-O-azidomethyl claim 3 , 3′-aminoxy or 3′-O-allyl group.6Saccharomyces cerevisiae.. The method as defined in claim 3 , wherein the terminal deoxynucleotidyl transferase (TdT) is added in the presence of an extension solution comprising one or more buffers claim 3 , such as Tris or cacodylate claim 3 , one or more salts; and/or inorganic pyrophosphatase claim 3 , such as purified claim 3 , recombinant inorganic pyrophosphatase from7. The method as defined in claim 3 , wherein step (b) is performed at a pH range of between 5 and 10 ...

PROPYLENE HOMOPOLYMERS AND METHODS OF MANUFACTURING THEM.

Una composición de polímero de propileno que comprende: homopolímero de propileno isotáctico con una distribución del peso molecular en el intervalo desde 3, 0 hasta 8, 0, un punto de fusión mayor que 150ºC y compuestos extraíbles en hexano menores que 1, 0 por ciento en peso, en la que una película de 50, 8 mm x 50, 8 mm x 508 my-m formada de la composición de polímero de propileno exhibe un estiramiento uniforme entre los intervalos de temperatura desde 151, 7ºC hasta 157, 2ºC cuando se estira hasta un espesor final estirado de 19, 1 µm en un aparato de estiramiento biaxial T.M. Long después de precalentar la película durante 27 s y estirar la película a una velocidad de 76, 2 mm/s. A propylene polymer composition comprising: isotactic propylene homopolymer with a molecular weight distribution in the range from 3.0 to 8.0, a melting point greater than 150 ° C and hexane extractable compounds less than 1.0 percent by weight, in which a 50.8 mm x 50.8 mm x 508 m-m film formed of the propylene polymer composition exhibits uniform stretching between temperature ranges from 151.7 ° C to 157.2 ° C when stretches to a final stretched thickness of 19, 1 µm in a biaxial TM stretch apparatus Long after preheating the film for 27 s and stretching the film at a speed of 76.2 mm / s.

Heat sealable blend of very low density polyethylene or plastomer with polypropylene based polymers and heat sealable film and articles made thereof

Disclosed are heat sealable compositions comprising: (a) from about 30 to about 70 weight percent a low melting polymer comprising an ethylene based copolymer having a density of from about 0.88 g/cm 3 to about 0.915 g/cm 3 , a melt index of from about 1.5 dg/min to about 7.5 dg/min, a molecular weight distribution no greater than about 3.5, and a composition breadth index greater than about 70 percent; and, (b) from about 70 to about 30 weight percent of a propylene based polymer having from about 88 mole percent to about 100 mole percent propylene and from about 12 mole percent to about 0 mole percent of an alpha-olefin other than propylene. Further disclosed are films and articles made thereof.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6–15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6.15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Modified polypropylene, process for making and article made from the same

A modified polypropylene having a substantially isotactic homopolypropylene and a propylene/olefin random copolymer, the modified polypropylene including up to about 50 chain disruptors per 1000 propylene repeat units. The chain disruptors are racemic polypropylene diads and olefin, the olefin being incorporated into the high end of the molecular weight distribution of the modified polypropylene.

Articles formed from propylene diene copolymers

Articles formed from propylene diene copolymers

The copolymerization reaction of one or more olefin monomers, such as propylene, with α,φ-diene units and the resulting copolymers are provided. More specifically, the copolymer may have from 90 to 99.999 weight percent of olefins and from 0.001 to 2.000 weight percent of α,φ-dienes. The copolymer may have a weight average molecular weight in the range from 50,000 to 2,000,000, a crystallization temperature (without the use of externally added nucleating agents) in the range from 115 °C to 135 °C and a melt flow rate in the range from 0.1 dg/min to 100 dg/min. These copolymers may be employed in a wide variety of applications, the articles of which include, for example, films, fibers, such as spunbonded and meltblown fibers, fabrics, such as nonwoven fabrics, and molded articles. The copolymer may further include at least two crystalline populations. Desirably, the melting point range of one of the crystalline populations is distinguishable from the melting point range of another crystalline population by a temperature range of from 1 °C to 16 °C. More desirably, one of the crystalline populations has a melting point in the range from 152 °C to 158 °C and another crystalline population has a melting point in the range from 142 °C to 148 °C.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or parallel polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or parallel polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6.15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Propylene homopolymers and methods of making the same

This invention relates to isotactic propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from about 2.5 to about 20.0. The isotactic propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or parallel polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Propylene homopolymers and methods of making the same

This invention relates to isotactic propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from about 2.5 to about 20.0. The isotactic propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages.

Polypropylene composoitions methods of making the same

This invention relates to propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from 4.0 to 20.0. The propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages. The composition may comprise isotactic homopolymer in one embodiment, and have a hexane extractables of less than 2 wt% in one embodiment. The composition is useful in making films.

Propylene polymers for films

Shrink films from propylene polymers

Shrink films prepared from metallocene catalyzed propylene homopolymers and copolymers are provided. The films exhibit a unique balance of properties as compared to known shrink films including higher stiffness, tensile strength and moisture barrier, lower extractables, improved shrinkage and increased shrink tension. In addition, the shrink behavior of the film can be substantially tailored by modifying the amount of comonomer present in the propylene polymer.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6.15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or paralled polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or paralled polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Propylene polymers for films

This invention relates generally to crystalline propylene polymers, to methods for their production and to methods for their use in film applications. Specifically, this invention relates to crystalline propylene polymers comprising both propylene homopolymer and propylene copolymer. The compositions are prepared using metallocene catalyst systems comprising at least two metallocenes in a polymerization process that involves the sequential or paralled polymerization of propylene homopolymer and copolymer using propylene with a small amount of comonomer, preferably ethylene. The polymerization is catalyzed by a dual metallocene catalyst system. The resulting polymers have a broad, bimodal molecular weight distribution. The resulting polymers are excellent for use in the production of biaxially oriented films or non-oriented films. Films prepared with these propylene polymers have a significantly broader processability range and can be evenly stretched at lower temperature compared to films prepared from traditional propylene polymer.

Polypropylene polymers

Embodiments of the present invention include a polypropylene homopolymer synthesized from a metallocene catalyst system and methods of forming the homopolymer, the homopolymer having an aluminium and chlorine recoverables value of less than 25 ppm and a xylene solubles of less than 1 wt% relative to the total weight of the homopolymer. The resulting homopolymer has other desirable properties such as a heat deflection temperature at 0.45 MPa of from 90 °C to 110°C, and a MWD value of from 1.7 to 5.0. These properties make embodiments of the homopolymer desirable for films, and in particular for capacitor films.

Shrink films from propylene polymers

Shrink films prepared from metallocene catalyzed propylene homopolymers and copolymers are provided. The films exhibit a unique balance of properties as compared to known shrink films including higher stiffness, tensile strength and moisture barrier, lower extractables, improved shrinkage and increased shrink tension. In addition, the shrink behavior of the film can be substantially tailored by modifying the amount of comonomer present in the propylene polymer.

Shrink films from propylene polymers

Shrink films prepared from metallocene catalyzed propylene homopolymers and copolymers are provided. The films exhibit a unique balance of properties as compared to known shrink films including higher stiffness, tensile strength and moisture barrier, lower extractables, improved shrinkage and increased shrink tension. In addition, the shrink behavior of the film can be substantially tailored by modifying the amount of comonomer present in the propylene polymer.

Propylene homopolymers and methods of making the same

This invention relates to isotactic propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from about 2.5 to about 20.0. The isotactic propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages.

PROPYLENEHOMOPOLYMERS AND MANUFACTURING METHOD

Propylene homopolymers and methods of making the same

This invention relates to isotactic propylene homopolymer compositions obtained from metallocene catalysis wherein the polymer has a molecular weight distribution (Mw/Mn) in the range of from about 2.5 to about 20.0. The isotactic propylene homopolymer composition may be prepared in a multiple stage polymerization process using the same metallocene component in at least two stages.

Polypropylene polymers

Embodiments of the present invention include a polypropylene homopolymer synthesized from a metallocene catalyst system and methods of forming the homopolymer, the homopolymer having an aluminium and chlorine recoverables value of less than 25 ppm and a xylene solubles of less than 1 wt% relative to the total weight of the homopolymer. The resulting homopolymer has other desirable properties such as a heat deflection temperature at 0.45 MPa of from 90 °C to 110°C, and a MWD value of from 1.7 to 5.0. These properties make embodiments of the homopolymer desirable for films, and in particular for capacitor films.

Polypropylene polymers

Embodiments of the present invention include a polypropylene homopolymer synthesized from a metallocene catalyst system and methods of forming the homopolymer, the homopolymer having an aluminium and chlorine recoverables value of less than 25 ppm and a xylene solubles of less than 1 wt% relative to the total weight of the homopolymer. The resulting homopolymer has other desirable properties such as a heat deflection temperature at 0.45 MPa of fr om 90 ~C to 110~C, and a MWD value of from 1.7 to 5.0. These properties make embodiments of the homopolymer desirable for films, and in particular for capacitor films.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6.15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Polypropylene films

The present invention provides isotactic polypropylene compositions suitable for cast film applications, cast polypropylene films made therefrom, and processes for forming such films. The novel polypropylene films are formed from film resins having a melt flow ratio of from 6.15 dg/min, with a narrow molecular weight distribution, narrow composition distribution, low level of solvent extractables, and increased film clarity (i.e., decreased haze %) compared to prior art Ziegler-Natta polypropylene film resins. The polypropylene films can be cast from an extruded polypropylene polymer, the extruded isotactic polypropylene polymer being formed by polymerization with a fluorided silica supported catalyst.

Polypropylene composoitions methods of making the same

Industrial yeast comprising an integrated glucoamylase gene

A vector having a gene for resistance to an antibiotic otherwise capable of killing a host yeast cell, the gene being transcribed from a yeast promoter sequence and the vector being capable of being integrated into a chromosome of the host yeast cell; and a diploid or greater ploidy yeast cell transformed by such a vector with heterologous DNA.

Recombinant deoxyribonucleic acid which codes for plasminogen activator

The present invention provides a deoxyribonucleic acid (DNA) segment related to a human plasminogen activator gene. The segment is inserted into a plasmid vector which in turn can be incorporated into a bacterium or other microorganism. The bacterium can then be cultured to produce a plasminogen activator protein having properties of human urokinase.

Compositions and methods for treating or preventing pneumococcal infection

Nucleotide derivatives containing amine masked moieties and their use in a templated and non-templated enzymatic nucleic acid synthesis

The invention relates to the use of an amine masked moiety in a method of enzymatic nucleic acid synthesis. The invention also relates to said amine masked moieties

Resinous binder compositions

Compositions and methods intended to treat or prevent pneumococcal infection

Composición que comprende un polipéptido conjugado con un polisacárido capsular de Streptococcus pneumoniae, en la que el polipéptido comprende un fragmento de por lo menos 400 aminoácidos contiguos de una proteína neumolisina de Streptococcus pneumoniae, careciendo el polipéptido de la secuencia de aminoácidos KVEND (SEC ID N.º: 22), careciendo el polipéptido de actividad hemolítica, consistiendo el polipéptido en una secuencia de aminoácidos seleccionada de entre los aminoácidos 1 a 465 de SEC ID N.º: 1, los aminoácidos 1 a 464 de SEC ID N.º: 1, los aminoácidos 1 a 469 de SEC ID N.º : 1, y los aminoácidos 1 a 470 de SEC ID N.º: 1 y provocando la composición una respuesta inmunitaria contra el Streptococcus pneumoniae cuando se administra a un mamífero. Composition comprising a polypeptide conjugated to a capsular polysaccharide of Streptococcus pneumoniae, in which the polypeptide comprises a fragment of at least 400 contiguous amino acids of a pneumolysin protein of Streptococcus pneumoniae, the polypeptide lacking the amino acid sequence KVEND (SEQ ID N : 22), the polypeptide lacking hemolytic activity, the polypeptide consisting of an amino acid sequence selected from amino acids 1 to 465 of SEQ ID NO: 1, amino acids 1 to 464 of SEQ ID NO: 1, amino acids 1 to 469 of SEQ ID NO: 1, and amino acids 1 to 470 of SEQ ID NO: 1 and the composition eliciting an immune response against Streptococcus pneumoniae when administered to a mammal.

Compositions of resinous binding agents

Lipid coatings for implantable medical devices

Disclosed herein are medical devices, such as stents, comprising a porous substrate, and a composition coating and/or impregnating the porous substrate where the composition comprises a bioresorbable carrier (e.g., at least one lipid) and at least one pharmaceutically active agent.

Device for cutting or heating medical implants

The present invention relates to a hand-held device for cutting or heating medical implants, in particular for cutting and bending resorbable implants. The device comprises a heating element electrically connectable to a power source (e.g., a battery), a switch for selectively completing the circuit between the heating element and the power source, and a housing for enclosing the battery and associated electrical connections. The invention is directed to a kit comprising a handle assembly and multiple interchangeable cutting or heating tips for use therewith. One tip member is configured for heating an implant to a sufficient temperature to cut the implant while a second tip member is configured forheating the implant to a sufficient temperature to bend the implant. A tip member housing an additional power source may be provided to bend larger size implants.

Lipid coatings for implantable medical devices

Disclosed herein are medical devices, such as stents, comprising a porous substrate, and a composition coating and/or impregnating the porous substrate where the composition comprises a bioresorbable carrier (e.g., at least one lipid) and at least one pharmaceutically active agent.

Method of nucleic acid synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3'-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

Methods of treating respiratory disease with deupirfenidone

Disclosed herein is a method of treating a viral, e.g., SARS-CoV-2, respiratory disease or infection, such as COVID-19 related pneumonia, that includes administering deuterium-enriched pirfenidone, e.g., daily for 3 months or more, such that the viral respiratory disease or infection is treated. The treating is effective in preventing the development of, halting the progression of, or slowing the progression of one or more of pulmonary fibrosis, respiratory complications of the viral respiratory disease or infection, respiratory symptoms of the viral respiratory disease or infection or pulmonary dysfunction.

Method of coating medical devices

Disclosed herein are medical devices, such as stents, comprising a porous substrate, such as a porous ceramic. Also disclosed herein are methods for impregnating the porous substrate with a composition comprising at least one lipid and at least one pharmaceutically active agent, where the porous substrate is microporous and/or nanoporous.

Lipid coatings for implantable medical devices

Disclosed herein are medical devices, such as stents, comprising a porous substrate, and a composition coating and/or impregnating the porous substrate where the composition comprises a bioresorbable carrier (e.g., at least one lipid) and at least one pharmaceutically active agent.

Gegenstände aus propylen-dien-copolymere

Methods of treating lymphedema with deupirfenidone

Methods of treating interstitial lung diseases and other fibrotic-mediated pulmonary diseases and disorders with deupirfenidone

Disclosed herein is a method of treating interstitial lung disease and other fibrotic-mediated pulmonary diseases or disorders. The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 825 mg to about 2475 mg.

Compositions and methods related to nucleic acid synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

A process for the preparation of nucleic acid by means of 3'-o-azidomethyl nucleotide triphosphate

Methods of treating fibrotic- and collagen-mediated diseases and disorders with deupirfenidone

Disclosed herein is a method of treating fibrotic- and collagen-mediated diseases or disorders. The method includes administering to a subject in need thereof deuterium-enriched pirfenidone.

Harzartige bindemittelzubereitungen

System and method for activation and deactivation of cued health assessment

A system for activating a cued health assessment, which includes an audio receiver for receiving voice samples to measure one of a plurality of voice biomarkers, an audio processing module for extracting one of a plurality of biomarkers from the received voice samples, the audio processing module further classifies the received voice samples to one of plurality of predetermined health states according to the extracted biomarkers, and a voice sample scheduler for activating a cued health assessment module when the classified health state is a clinically actionable health state.

System and method for activation and deactivation of cued health assessment

A system for activating a cued health assessment, which includes an audio receiver for receiving voice samples to measure one of a plurality of voice biomarkers, an audio processing module for extracting one of a plurality of biomarkers from the received voice samples, the audio processing module further classifies the received voice samples to one of plurality of predetermined health states according to the extracted biomarkers, and a voice sample scheduler for activating a cued health assessment module when the classified health state is a clinically actionable health state.

System and method for activation and deactivation of cued health assessment

A system for activating a cued health assessment, which includes an audio receiver for receiving voice samples to measure one of a plurality of voice biomarkers, an audio processing module for extracting one of a plurality of biomarkers from the received voice samples, the audio processing module further classifies the received voice samples to one of plurality of predetermined health states according to the extracted biomarkers, and a voice sample scheduler for activating a cued health assessment module when the classified health state is a clinically actionable health state.

System and method for activation and deactivation of cued health assessment

A system for activating a cued health assessment, which includes an audio receiver for receiving voice samples to measure one of a plurality of voice biomarkers, an audio processing module for extracting one of a plurality of biomarkers from the received voice samples, the audio processing module further classifies the received voice samples to one of plurality of predetermined health states according to the extracted biomarkers, and a voice sample scheduler for activating a cued health assessment module when the classified health state is a clinically actionable health state.

System and method for activation and deactivation of cued health assessment

Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 2500 mg.

A process for the preparation of nucleic acid by means of 3'-o-azidomethyl nucleotide triphosphate

The invention relates to a method of nucleic acid synthesis comprising the use of 3'-O- azidomethyl blocked nucleotide triphosphates which comprises the step of adding a capping group to any uncleaved 3'-O-azidomethyl groups and to the use of kits comprising said capping groups in a method of nucleic acid synthesis. The invention also relates to capped nucleotide triphosphates and 3'-O-azidomethyl capping groups.

Methods of treating diseases and disorders with deupirfenidone

Disclosed herein are methods of treating a fibrotic-mediated disorder or a collagen-mediated disorder, that include administering to a subject in need thereof a high dose of deupirfenidone, e.g., a total daily dose of up to 2500 mg. Also disclosed are interventional dosing for functionally impairing diseases and dosing for chronic disease.

Methods of treating respiratory disease with deupirfenidone

Deuterium-enriched pirfenidone and methods of use thereof

Disclosed herein are deuterium-enriched N-Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Novel use

The invention relates to the use of polyphosphate containing species in a method of nucleic acid synthesis, to methods of nucleic acid synthesis, and to the use of kits comprising said polyphosphate containing species. The invention also relates to the use of polyphosphate containing species for the capping of 3'-terminal hydroxyl moieties using terminal transferases.

Compositions and Methods Related to Nucleic Acid Synthesis

The invention relates to the use of specific terminal deoxynucleotidyl transferase (TdT) enzymes in a method of nucleic acid synthesis, to methods of synthesizing nucleic acids, and to the use of kits comprising said enzymes in a method of nucleic acid synthesis. The invention also relates to the use of terminal deoxynucleotidyl transferases and 3′-blocked nucleotide triphosphates in a method of template independent nucleic acid synthesis.

System and method for activation and deactivation of cued health assessment

System and method for activation and deactivation of cued health assessment Abstract A system for activating a cued health assessment, which includes an audio receiver for receiving voice samples to measure one of a plurality of voice biomarkers, an audio processing module for extracting one of a plurality of biomarkers from the received voice samples, the audio processing module further classifies the received voice samples to one of plurality of predetermined health states according to the extracted biomarkers, and a voice sample scheduler for activating a cued health assessment module when the classified health state is a clinically actionable health state.

Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 2500 mg.

Methods of treating idiopathic pulmonary fibrosis with deupirfenidone

Disclosed herein is a method of treating Idiopathic Pulmonary Fibrosis (IPF). The method includes administering to a subject in need thereof the deuterium-enriched pirfenidone LYT-100 at a total daily dose from about 1650 mg to about 2500 mg.

Azidomethyl ether deprotection method

The invention relates to a method of converting an azidomethyl ether substituent to a free hydroxyl group. The invention also relates tomethods of nucleic acid synthesis and sequencing comprising the use of nucleotide triphosphates having a 3'-O-azidomethyl substituent, to kitscomprising nucleotide triphosphates having a 3'-O-azidomethyl substituent and photoactivatable transition metal complex and to the use of said kits in methods of nucleic acid synthesis and sequencing.

Method of coating medical devices

Disclosed herein are medical devices, such as stents, comprising a porous substrate, such as a porous ceramic. Also disclosed herein are methods for impregnating the porous substrate with a composition comprising at least one lipid and at least one pharmaceutically active agent, where the porous substrate is microporous and/or nanoporous.

Deuterium-enriched pirfenidone and methods of use thereof

Disclosed herein are deuterium-enriched N Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.

Deuterium-enriched pirfenidone and methods of use thereof

Disclosed herein are deuterium-enriched N Aryl pyridinone compounds, optionally in combination with one or more additional therapeutic agents, pharmaceutical compositions comprising the same, methods of preparation thereof, and methods of use thereof. Such compounds and compositions are useful, for example, in treating diseases, disorders, or conditions such as edema.